Fig. 4

Siglec-15 was a direct target of miR-4786 in bladder cancer. A Real-time PCR analysis of miR-4786 expression in bladder tumor samples with paired adjacent normal tissues. B Correlation analysis between miR-4786 and Siglec-15 in bladder tumors (n = 100). C Change of miR-4786 expression in both HT1197 and SW780 cells in response to miR-4786 inhibitor (upper) and Siglec-15 was determined accordingly (lower). D Change of miR-4786 expression in both UMUC-3 and T24 cells in response to miR-4786 mimic (upper) and Siglec-15 was determined accordingly (lower). E Western blot analysis of Siglec-15 proteins in UMUC3 and T24 cells transfected with either control or miR-4786 mimic (left), as well as HT1197 and SW780 cells transfected with either negative control (miR-NC) or miR-4786-specific inhibitor (right), and the croppted blots were presented correspondingly. F Immunofluorescence staining of cell surface Siglec-15 in HT1197 cells transfected with either control or miR-4786 inhibitor. G Alignment between miR-4786 seed region and both wild-type and putative binding site-mutated Siglec-15 3ʹUTR. H Luciferase reporter analysis of the potential regulatory effects of miR-4786 on Siglec-15 in 293 T cells, which were transfected with control, miR-4786 mimics, and miR-4786 inhibitors, respectively